Dec 18 $220 / $260 Bull Call Spread
Buy 1x $220C · Sell 1x $260C · 32d
Multi-horizon algorithmic price targets, Wall Street consensus calibration, reverse-DCF growth expectations & options volatility valuation
Synthesized fundamental, multiple & technical thesis for MRNA
MRNA Price Forecast 2027: Our AI models project that MRNA stock will fall to approximately $165.32 by 2027. This represents a potential 17.1% contraction from the current trading price of $199.33. The overall market sentiment for MRNA is currently bearish, based on a combination of proprietary technical signals and fundamental analysis.
Fundamental Analysis: Trading with its most recent quarterly earnings growing by -85.1%. MRNA shows a complex fundamental profile. Our model evaluates these metrics alongside sector peers and historical performance to derive the 2027 price target. If the company exceeds its current growth projections, there may be further upside beyond our base case scenario.
Technical Outlook: The stock is technically in a downtrend phase. The Relative Strength Index (RSI) is currently 41.4, which suggests the stock is trading in a neutral range. Traders should monitor key support and resistance levels closely, as a breakout or breakdown from current price consolidation will be the primary catalyst for the stock reaching the 2027 predicted target.
Composite equity rating reconciled with 1-year target trajectory
Projected price curve from spot ($199.33) across 30D–3Y horizons
Calibrated to Wall Street consensus curve
| Horizon | Target Price | Implied Return |
|---|---|---|
| 30 Days Near-Term | $196.61 | -1.4% |
| 90 Days 1 Quarter | $190.83 | -4.3% |
| 6 Months Medium-Term | $182.32 | -8.5% |
| 1 Year Base Model | $165.32 | -17.1% |
Probability-weighted regime outcomes around the 12-month forecast horizon
Best case scenario if strong fundamentals and market conditions align
Expected scenario based on current growth trajectory
Downside scenario if market headwinds or disappointing results
Compare $21,527 for 100 MRNA shares against risk-defined 5-day option spreads and long-dated LEAP structures.
Buy 1x $220C · Sell 1x $260C · 32d
Sell 1x $190P · Buy 1x $180P · 32d
Sell 1x $190P · Buy 1x $220/$260C · 32d
Proprietary deep-tech expectations gap, supply-chain bottleneck scoring & patent/filing velocity
PEG-adjusted intrinsic valuation & balance-sheet multiples
Momentum oscillators, volume accumulation & key price levels
Volume-weighted price action shows near-term supply/distribution pressure; watch support levels for stabilization.
Comparing LEAP Call Implied Volatility & Breakeven against the 1-Year Model Target — Derivative Strategy Signal, NOT an Equity Stock Rating
Short-term institutional sweep & implied volatility anomaly monitor (distinct from long-term equity rating)
Deep-dive valuation models, options chain analytics & head-to-head peer comparisons
Based on our AI analysis, MRNA is predicted to reach $165.32 by 2027, representing a potential 17.1% decrease from the current price of $199.33.
Our analysis rates MRNA as a HOLD (AI Quant Score 40.7/100) based on current technical and fundamental indicators. With a projected 17.1% downside in our 1-year constant-P/E model, investors should consider their risk tolerance and investment horizon.
MRNA has a 52-week high of $280.80 and a 52-week low of $22.28. The stock is currently trading 29.0% below its 52-week high.
MRNA is currently in a downtrend trend. The RSI of 41.4 indicates the stock is trading in neutral territory. Traders should monitor support and resistance levels for potential entry points.